METHODS AND KITS FOR BREAST CANCER PROGNOSIS
Innovative Products and Technologies
Technology Offer
METHODS AND KITS FOR BREAST CANCER PROGNOSIS
- RAMOT at Tel Aviv University Ltd.
- From Israel
- Responsive
- Innovative Products and Technologies
Summary of the technology
Diagnosis of the metastatic state of breast tumors has fundamental significance for the determination of prognosis and treatment modalities. In the current work we performed genome scale proteomic profiling of breast tumors, and compared pre-metastatic (lymph-node negative) and metastatic (lymph-node positive) breast tumors. Using machine learning algorithms, we identified a proteomic signature of 134 proteins that can distinguish (as a signature) between pre- and post-metastatic tumors. Among the proteins that were upregulated in the metastatic tumors (58 tumors) we identified a group of ribosomal proteins, splicing factors, and proteins belonging to the electron-transport chain complexes
Project ID : 5-2016-977
Details of the Technology Offer
THE NEED
Despite the overall good prognosis of luminal breast cancers, risk of recurrence rises substantially if the cancer had already metastasized to nearby lymph nodes by the time of diagnosis. While lymph node negative patients may benefit from endocrine therapy alone, the standard of care for lymph-node positive patients remains adjuvant chemotherapy. Hence the lymph node status is emphasized as a crucial component in treatment decision-making.
The unfolding of the 'omics' era allowed for the use of large-scale data to assist in the prediction of several important clinical features of cancer, such as the risk for recurrence, tumor aggressiveness and response to therapy, and several commercial assays were developed as a result, all of them based on gene expression profiling. These include OncotypeDX, Prosigna and MammaPrint, which determine risk of recurrence of luminal breast cancer. While some of these tests are widely used in the clinic, they still suffer from highly inaccurate risk estimates. Proteomics makes a natural complement to the genomic and transcriptomic studies, but in contrast to these, as proteins convey the actual functional properties of cells these much better reflect the cancer phenotype. Mass spectrometry (MS)-based proteomic analyses have undergone a revolution in the past decade, owing to improvements in instrumentation, sample preparation and quantification methods. Current state of the art MS-based proteomics provides accurate, quantitative and wide measures of protein abundance.
TECHNOLOGY
We developed a protein-based signature that determines the metastatic state of luminal breast cancer based on the proteomic profile of the primary tumor. This signature aims to relieve the need for multiple lymph nodes biopsies, which increase inflammation and potential complications. This 15-protein signature was extracted from genome-scale quantitative proteomics research using supervised classification algorithms. It shows high specificity and sensitivity with an AUC of a ROC curve of 0.93. This is the first proteomic signature that allows such a classification.
ADVANTAGES
• Determine the aggressiveness of the tumor already by the initial biopsy
• Obliterating the need for intrusive surgical disruption of the lymph nodes
• Prevent unnecessary systemic treatment.
PATENTS
Patent Pending
Despite the overall good prognosis of luminal breast cancers, risk of recurrence rises substantially if the cancer had already metastasized to nearby lymph nodes by the time of diagnosis. While lymph node negative patients may benefit from endocrine therapy alone, the standard of care for lymph-node positive patients remains adjuvant chemotherapy. Hence the lymph node status is emphasized as a crucial component in treatment decision-making.
The unfolding of the 'omics' era allowed for the use of large-scale data to assist in the prediction of several important clinical features of cancer, such as the risk for recurrence, tumor aggressiveness and response to therapy, and several commercial assays were developed as a result, all of them based on gene expression profiling. These include OncotypeDX, Prosigna and MammaPrint, which determine risk of recurrence of luminal breast cancer. While some of these tests are widely used in the clinic, they still suffer from highly inaccurate risk estimates. Proteomics makes a natural complement to the genomic and transcriptomic studies, but in contrast to these, as proteins convey the actual functional properties of cells these much better reflect the cancer phenotype. Mass spectrometry (MS)-based proteomic analyses have undergone a revolution in the past decade, owing to improvements in instrumentation, sample preparation and quantification methods. Current state of the art MS-based proteomics provides accurate, quantitative and wide measures of protein abundance.
TECHNOLOGY
We developed a protein-based signature that determines the metastatic state of luminal breast cancer based on the proteomic profile of the primary tumor. This signature aims to relieve the need for multiple lymph nodes biopsies, which increase inflammation and potential complications. This 15-protein signature was extracted from genome-scale quantitative proteomics research using supervised classification algorithms. It shows high specificity and sensitivity with an AUC of a ROC curve of 0.93. This is the first proteomic signature that allows such a classification.
ADVANTAGES
• Determine the aggressiveness of the tumor already by the initial biopsy
• Obliterating the need for intrusive surgical disruption of the lymph nodes
• Prevent unnecessary systemic treatment.
PATENTS
Patent Pending